STUDY OF DRUG-DRUG INTERACTION ON THE MANAGEMENT OF HYPERLIPIDEMIC DISEASE: SIMVASTATIN AND EZETIMIBE
This study was designed to investigate the effects of combination of ezetimibe and simvastatin on lipoproteins in patients with mixed dyslipidemia. Among the 482 patients screened 465 who met the inclusion criteria after 6weeks on a strict diet therapy were grouped into three treatment groups. The inclusion criteria were mixed dyslipidemia with a high triglyceride level (200-499 mg per 100ml) and a total cholesterol level more than 200mg per 100ml. Retrospective study was conducted on dyslipidemic patients receiving ezetimibe (10mg) alone, simvastatin (20mg) alone, and combination of simvastatin (20mg) and ezetimibe (10mg) daily for 24weeks. After 24 weeks treatment,(Tc, Tg, LDL)was found significantly decreased and HDL level increased in the combination therapy (Simvastatin and ezetimibe) than monotherapy. From the result it is concluded that combination therapy may be considered as an optimal treatment option for patients with mixed dyslipidemia.